The purpose of this study was to test whether the insulin sensitivity, lipid metabolism and the susceptibility of the heart to ischemia/reperfusion injury are modulated by the chronic estrogen status. Rats were ovariectomized (OVX), not ovariectomized (sham) or ovariectomized and treated with subcutaneous 17 -estradiol (30 μg/kg/day, OVX+E2) ( n=14–17 per group). Within 3 months after operation, body weight, the serum levels of estrogen, glucose, insulin, total cholesterol (T-chol), HDL-chol, LDL-cholesterol (LDL-chol), triglycerides (TG) and lipoprotein a (Lp(a)) were monitored. Three months after operation, hearts of partial rats ( n=6–8 per group) were isolated and allowed an initial 20-min stabilization period, and then cardiac function was recorded and creatine kinase (CK) release in the coronary effluent was measured after 4 h of hypothermic ischemia in isolated rat hearts. The experimental results showed that from 2 weeks after ovariectomy to the end of the study, body weights of OVX were significantly higher compared with the other two groups ( p<0.05). On weeks 5 and 9, insulin level of OVX was significantly higher than that of the other two groups ( p<0.05), whereas it was not different among the three groups on weeks 12 and 13 ( p>0.05). Blood glucose on week 13 was significantly higher in OVX ( p<0.05). Consequently, Insulin Sensitivity Index (ISI) of OVX was lower than that of the other two groups on weeks 5 and 9 ( p<0.05), but not on weeks 12 and 13. Serum values for T-chol, HDL-chol and LDL-chol were not significantly different among the three groups within the observing period. On week 13, TG level in ovariectomized group was significantly lower than in the sham- and E2-treated groups ( p<0.05). Compared with sham, Lp(a) level was slight increased in OVX rats ( p<0.05), while it was further increased in E2-treated rats ( p<0.05). Cardiac function (left ventricular pressure (LVP) and ±d p/d t max) of hearts removed from OVX rats was depressed, and CK release was markedly increased ( p<0.05). However, treatment with E2 significantly improved cardiac function, as shown by increasing left ventricular pressure,+d p/d t max and −d p/d t max, and decreased CK release. In conclusion, chronic E2 treatment has some beneficial effects on cardiovascular disease (CVD), which come from the results of improvement of insulin sensitivity and post-ischemia cardiac function. However, the mechanism did not include changes in lipids and lipoproteins. The change in Lp(a) level shows that estrogen does not confer cardiovascular protection and may increase the risk of stroke.
Read full abstract